Scancell
SCIB1 SCOPE study shows a striking 82% ORRScancell
Upcoming SCIB1 data could provide first proof of conceptScancell
Modi-1 successful in first part of Phase I/II trialScancell
A leader in antibody and vaccine oncology platformsScancell
FY22 results highlight clinical and corporate progressScancell
Optimum partner secured for first antibody dealScancell
First Moditope oncology vaccine enters the clinicScancell
A fresh impetus in delivering immune-oncology vaccinesScancell
CTA approval confirms H221 COVIDITY Phase I startScancell
COVIDITY programme to start Phase I in H221